ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 168 filers reported holding ASCENDIS PHARMA A/S in Q1 2023. The put-call ratio across all filers is 0.19 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,434,640 | -84.5% | 26,000 | -85.2% | 0.04% | -86.6% |
| Q2 2023 | $15,681,225 | -69.8% | 175,700 | -63.7% | 0.28% | -72.4% |
| Q1 2023 | $51,958,812 | +131.0% | 484,600 | +163.1% | 1.00% | +186.0% |
| Q4 2022 | $22,496,346 | -68.6% | 184,200 | -73.5% | 0.35% | -64.5% |
| Q3 2022 | $71,712,000 | +2028.6% | 694,472 | +2319.7% | 0.99% | +2372.5% |
| Q1 2022 | $3,369,000 | -45.1% | 28,701 | -37.1% | 0.04% | -41.2% |
| Q4 2021 | $6,135,000 | -3.8% | 45,600 | +14.0% | 0.07% | -5.6% |
| Q3 2021 | $6,376,000 | -73.6% | 40,000 | -78.2% | 0.07% | -77.1% |
| Q2 2021 | $24,113,000 | +196.1% | 183,300 | +190.0% | 0.31% | +80.5% |
| Q1 2021 | $8,143,000 | -5.7% | 63,200 | +1.8% | 0.17% | -40.0% |
| Q4 2019 | $8,639,000 | +95.1% | 62,100 | +35.1% | 0.29% | +26.1% |
| Q3 2019 | $4,429,000 | +92.3% | 45,979 | +129.9% | 0.23% | +98.3% |
| Q2 2019 | $2,303,000 | -87.3% | 20,000 | -87.0% | 0.12% | -88.4% |
| Q1 2019 | $18,101,000 | – | 153,800 | – | 1.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |